Oncologic imaging: A guiding hand of personalized cancer care

Radiology

Volumn 259, Issue 3, 2011, Pages 633-640

  Hricak, Hedvig ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODIHYDROTESTOSTERONE; GALLIUM 68; IMATINIB; IRINOTECAN; K RAS PROTEIN; RITUXIMAB; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG;

BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DRUG COST; DRUG EFFICACY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE QUALITY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERVENTIONAL RADIOLOGY; LUNG CANCER; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MOLECULAR IMAGING; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SOLID TUMOR; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TREATMENT RESPONSE; VOLUMETRY; WORLD HEALTH ORGANIZATION;

DIAGNOSTIC IMAGING; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; NORTH AMERICA; SOCIETIES, MEDICAL;

EID: 79956294257     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110252     Document Type: Conference Paper

References (45)

1. Boyle P, Levin B, eds. World Cancer Report 2008. Geneva, Switzerland: WHO Press, 2009.
2. Stephenson J. The World in Medicine: Cancer No. 1 killer by 2010. JAMA 2009;301(3):263.
3. American Cancer Society and Livestrong. Global economic cost of cancer report summary. http://www.cancer.org/acs/groups/content/@internationalaffairs/ documents/document/acspc-026203.pdf. Accessed November 1, 2010.
4. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010;376(9747):1186-1193.
5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758-2765.
6. Stadler ZK, Thom P, Robson ME, et al. Genome-wide association studies of cancer. J Clin Oncol 2010;28(27):4255-4267.
7. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363(4):301-304.
8. News page of the National Cancer Institute Web site. Lung cancer trial results show mortality benefit with low-dose CT: Twenty percent fewer lung cancer deaths seen among those who were screened with low-dose spiral CT than with chest X-ray. http://www.cancer.gov/newscenter/. Posted on November 4, 2010. Accessed November 15, 2010.
9. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screen ing with mammography for women ages 40 to 49 years: Evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer 2010;117(4):714-722.
10. Godoy MC, Cayne NS, Ko JP. Endovascular repair of the thoracic aorta: preoperative and postoperative evaluation with multidetector computed tomography. J Thorac Imaging 2010;26(1):63-73.
11. Wagner HN Jr, Conti PS. Advances in medical imaging for cancer diagnosis and treatment. Cancer 1991;67(4 Suppl):1121-1128.
12. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100(12):2655-2663. (Pubitemid 38715772)
13. Pantelis E, Papadakis N, Verigos K, et al. Integration of functional MRI and white matter tractography in stereotactic radiosurgery clinical practice. Int J Radiat Oncol Biol Phys 2010;78(1):257-267.
14. Stulak JMGC, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006;141(5):489-494; discussion 494-496.
15. Cleary K, Peters TM. Image-guided interventions: technology review and clinical applications. Annu Rev Biomed Eng 2010;12:119-142.
16. Dawson LA, Jaffray DA. Advances in image-guided radiation therapy. J Clin Oncol 2007;25(8):938-946. (Pubitemid 350002859)
17. World Health Organization. WHO handbook for reporting results of cancer treatment. Offset Publication No. 48. Geneva, Switzerland: World Health Organization, 1979.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
20. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361(23):2221-2229.
21. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol 2010;21(9):1751-1755.
22. Liu F, Zhao B, Krug LM, et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010;5(6):879-884.
23. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response - initial results. Radiology 2006;241(3):892-898. (Pubitemid 46190557)
24. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16(18):4647-4653.
25. Buckler AJ, Schwartz LH, Petrick N, et al. Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. Opt Express 2010;18(14):15267-15282.
26. Harris GJ, Plotkin SR, Maccollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008;62(6):1314-1319; discussion 1319-1320.
27. Buckler AJ, Mozley PD, Schwartz L, et al. Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. Acad Radiol 2010;17(1):107-115.
28. Quantitative Imaging Biomarkers Alliance Page. Radiological Society of North America Web site. http://www.rsna.org/Research/QIBA/. Accessed November 2, 2010.
29. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21(23):4342-4349. (Pubitemid 46621810)
30. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45(3):366-373. (Pubitemid 47618608)
31. Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: National Academies Press, 2010.
32. Tuma RS. Economic analysis: big savings with KRAS testing. Oncology Times, March 25, 2009; 42-43.
33. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-1417.
34. Capala J, Bouchelouche K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol 2010;22(6):559-566.
35. Cho H, Ackerstaff E, Carlin S, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009;11(3):247-259, 2p, 259.
36. Lee DY, Li KC. Systems diagnostics: the systems approach to molecular imaging. AJR Am J Roentgenol 2009;193(2):287-294.
37. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790.
38. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-1446.
39. Mayer-Kuckuk P, Doubrovin M, Bidaut L, et al. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant 2006;15(1):75-82.
40. Warner S. Diagnostics + therapy = theranostics. Scientist 2004;18(16):38-39. (Pubitemid 39296422)
41. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22(6):701-706. (Pubitemid 38702826)
42. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond) 2008;3(2):137-140. (Pubitemid 351611851)
43. Helwick C. High discordance between primary breast cancer and recurrence observed in three large trials. The ASCO Post. Cold Spring Harbor, New York: American Society of Clinical Oncology and Harborside Press, 2010.
44. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008;105(33):11613-11618.
45. Welch MJ, Hawker CJ, Wooley KL. The advantages of nanoparticles for PET. J Nucl Med 2009;50(11):1743-1746.